哌拉西林与氨苄西林舒巴坦治疗社区获得性细菌性肺炎的临床对照研究

目的评价哌拉西林与氨苄西林舒巴坦对治疗社区获得性细菌性肺炎的临床有效性。方法选择轻到重度社区获得性细菌性肺炎患者作为研究对象,将其分为两组:哌拉西林组(静脉给予2.0 g,每日2次)和氨苄西林舒巴坦组(静脉给予3.0 g,每日2次),疗程7 d,可按需延长到14 d,观察两组的临床疗效、细菌学有效性及副作用等。结果哌拉西林组的总有效率[77.4%(123/159)]与氨苄西林舒巴坦组的总有效率[67.3%(99/147)]比较,差异无统计学意义(P>0.05),但哌拉西林组在对有基础疾病患者的治愈率高于氨苄西林舒巴坦组(P<0.05)。两组最常见的致病菌均为肺炎链球菌,副作用均较轻,差异无统计学意义(P>0.05)。结论哌拉西林治疗组有较好的治愈率和耐受性,对有基础疾病的肺炎患者也有较高的治愈率,值得成为社区获得性细菌性肺炎的一线疗法。

Clinical comparative study on Piperacillin and Ampicillin Sulbactam in the treatment of community-acquired bacterial pneumonia

Objective To evaluate the clinical usefulness of Piperacillin therapy for community-acquired pneumonia com pared to Ampicillin Sulbactam.Methods The patients with mild to severe community-acquired bacterial pneumonia were chosen as subjects and divided into two groups： Piperacillin group（2.0 g iv,twice a day） and Ampicillin Sulbactam group（3.0 g iv,twice a day）,7 days was as a course,which can be extended to 14 days as needed.The clinical efficacy,bacteri ology effectiveness and adverse reactions of the two groups were observed.Results There were no significant differences in the total effective rate between Piperacillin group [77.4%（123/159）] and Ampicillin Sulbactam group [67.3%（99/147）]（P〉0.05）,but the curative rate for the patients with underlying diseases of Piperacillin group was higher than that of Ampi cillin Sulbactam group（P〈0.05）.The most common pathogenic bacterium of the two groups was both streptococcus pneu monia,and the adverse reactions were both light,with no significant differences（P〉0.05）.Conclusion Piperacillin group has good efficiency and tolerability and that it may be highly effective,even in cases of pneumonia with underlying dis eases.This regimen may thus serve as a first line treatment of community-acquired pneumonia.